- Home
- ACIC vs ZVRA Comparison
ACIC vs ZVRA Comparison
Compare ACIC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | ZVRA |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.5M | 653.2M |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ACIC | ZVRA |
|---|---|---|
| Price | $10.80 | $10.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 226.1K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | 39.61 | ★ 159.21 |
| EPS | 0.39 | ★ 0.60 |
| Revenue | ★ $335,439,000.00 | $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | $1.00 | $53.42 |
| P/E Ratio | $27.77 | ★ $17.53 |
| Revenue Growth | 13.07 | ★ 350.91 |
| 52 Week Low | $9.80 | $7.16 |
| 52 Week High | $13.06 | $13.16 |
Technical Indicators
Market Signals| Indicator | ACIC | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 45.03 |
| Support Level | $10.79 | $8.30 |
| Resistance Level | $11.53 | $10.15 |
| Average True Range (ATR) | 0.46 | 0.66 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 46.95 | 1.71 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.